A nested case-control study of adjuvant hormonal therapy persistence and compliance, and early breast cancer recurrence in women with stage I-III breast cancer

British Journal of Cancer

Volumn 109, Issue 6, 2013, Pages 1513-1521

  Barron, T I ^a   Cahir, C ^a   Sharp, L ^b   Bennett, K ^a  

^a TRINITY COLLEGE DUBLIN   (Ireland)

^b NATIONAL CANCER REGISTRY IRELAND   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANASTROZOLE; ESTROGEN RECEPTOR; EXEMESTANE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LETROZOLE; TAMOXIFEN; TOREMIFENE;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER STAGING; CASE CONTROL STUDY; CONTROLLED STUDY; DISEASE SEVERITY; EARLY CANCER; FEMALE; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; MEDICATION COMPLIANCE; PATIENT COMPLIANCE; PRIORITY JOURNAL; RECURRENCE RISK; TREATMENT REFUSAL;

ADULT; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CASE-CONTROL STUDIES; FEMALE; HUMANS; MEDICATION ADHERENCE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING;

EID: 84884597255     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2013.518     Document Type: Article

References (45)

1. Ahern TP, Pedersen L, Tarp M, Cronin-Fenton DP, Garne JP, Silliman RA, Sørensen HT, Lash TL (2011) Statin prescriptions and breast cancer recurrence risk: A danish nationwide prospective cohort study. J Natl Cancer Inst 103: 1461-1468.
2. Austin PC (2008) Assessing balance in measured baseline covariates when using many-to-one matching on the propensity-score. Pharmacoepidemiol Drug Saf 17: 1218-1225.
3. Barron TI, Bennett Kathleen, Feely J (2010) A competing risks prescription refill model of compliance and persistence. Value Health 13: 796-804.
4. Barron TI, Connolly R, Bennett K, Feely J, Kennedy MJ (2007) Early discontinuation of tamoxifen. Cancer 109: 832-839.
5. Benner JS, Glynn RJ, Mogun H, Neumann PJ, Weinstein MC, Avorn J (2002) Long-term persistence in use of statin therapy in elderly patients. JAMA 288: 455-461.
6. Bergstralh EJ, Kosanke JL (1995) Computerized matching of controls (Section of Biostatistics Technical Report No. 56). Mayo Foundation
7. Bonadonna G, Valagussa P (1981) Dose-response effect of adjuvant chemotherapy in breast cancer. N Engl J Med 304: 10-15.
8. Bosco JLF, Lash TL, Prout MN, Buist DSM, Geiger AM, Haque R, Wei F, Silliman RA (2009) Breast cancer recurrence in older women five to ten years after diagnosis. Cancer Epidemiol Biomarkers Prev 18: 2979-2983.
9. Bradley CJ, Given CW, Roberts C (2002) Race, socioeconomic status, and breast cancer treatment and survival. J Natl Cancer Inst 94: 490-496.
10. Braithwaite D, Izano M, Moore DH, Kwan ML, Tammemagi MC, Hiatt RA, Kerlikowske K, Kroenke CH, Sweeney C, Habel L, Castillo A, Weltzien E, Caan B (2012) Smoking and survival after breast cancer diagnosis: A prospective observational study and systematic review. Breast Cancer Res Treat 136: 521-533.
11. Brenner H, Savitz DA (1990) The effects of sensitivity and specificity of case selection on validity, sample size, precision, and power in hospital-based case-control studies. Am J Epidemiol 132: 181-192.
12. Curtis JR, Larson JC, Delzell E, Brookhart MA, Cadarette SM, Chlebowski R, Judd S, Safford M, Solomon DH, Lacroix AZ (2011) Placebo adherence, clinical outcomes, and mortality in the women's health initiative randomized hormone therapy trials. Med Care 49: 427-435.
13. Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, Abraham M, Alencar VHM, Badran A, Bonfill X, Bradbury J, Clarke M, Collins R, Davis SR, Delmestri A, Forbes JF, Haddad P, Hou M-F, Inbar M, Khaled H, Kielanowska J, Kwan W-H, Mathew BS, Müller B, Nicolucci A, Peralta O, Pernas F, Petruzelka L, Pienkowski T, Rajan B, Rubach MT, Tort S, Urrutia G, Valentini M, Wang Y, Peto R (2013) Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 381: 805-816.
14. Debled M, MacGrogan G, Brouste V, Mathoulin-Pelissier S, Durand M, Mauriac L (2007) Prognostic factors of early distant recurrence in hormone receptor-positive, postmenopausal breast cancer patients receiving adjuvant tamoxifen therapy: Results of a retrospective analysis. Cancer 109: 2197-2204.
15. Dezentjé VO, van Blijderveen NJC, Gelderblom H, Putter H, van Herk-Sukel MPP, Casparie MK, Egberts ACG, Nortier JWR, Guchelaar H-J (2010) Effect of concomitant CYP2D6 inhibitor use and tamoxifen adherence on breast cancer recurrence in early-stage breast cancer. J Clin Oncol 28: 2423-2429.
16. EBCTG (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 365: 1687-1717.
17. Fox MP, Lash TL, Greenland S (2005) A method to automate probabilistic sensitivity analyses of misclassified binary variables. Int J Epidemiol 34: 1370-1376.
18. Greene FL, Page DL, Fleming ID, Fritz A, Balch CM, Haller DG, Morrow M (2002) AJCC Cancer Staging Manual. 6th edn, Springer: New York.
19. Grunfeld EA, Hunter MS, Sikka P, Mittal S (2005) Adherence beliefs among breast cancer patients taking tamoxifen. Patient Edu Couns 59: 97-102.
20. Hadji P, Blettner M, Harbeck N, Jackisch C, Lück HJ, Windemuth-Kieselbach C, Zaun S, Kreienberg R (2012) The Patient's Anastrozole Compliance to Therapy (PACT) Program: A randomized, in-practice study on the impact of a standardized information program on persistence and compliance to adjuvant endocrine therapy in postmenopausal women with early breast cancer. Ann Oncol 24(6): 1505-1512.
21. Henry NL, Azzouz F, Desta Z, Li L, Nguyen AT, Lemler S, Hayden J, Tarpinian K, Yakim E, Flockhart DA, Stearns V, Hayes DF, Storniolo AM (2012) Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer. J Clin Oncol 30: 936-942.
22. Hershman DL, Shao T, Kushi LH, Buono D, Tsai WY, Fehrenbacher L, Kwan M, Gomez SL, Neugut AI (2011) Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat 126: 529-537.
23. Holmes MD, Chen WY, Li L, Hertzmark E, Spiegelman D, Hankinson SE (2010) Aspirin intake and survival after breast cancer. J Clin Oncol 28: 1467-1472.
24. Jurek AM, Lash TL, Maldonado G (2009) Specifying exposure classification parameters for sensitivity analysis: Family breast cancer history. Clin Epidemiol 1: 109-117.
25. Kelly A, Teljeur C Small Area Health Research Unit, Department of Public Health and Primary Care, Trinity College Dublin (2007) National Deprivation Index for Health Services and Health Services Research (Technical Report
26. Kennecke H, McArthur H, Olivotto IA, Speers C, Bajdik C, Chia SK, Ellard S, Norris B, Hayes M, Barnett J, Gelmon KA (2008) Risk of early recurrence among postmenopausal women with estrogen receptor-positive early breast cancer treated with adjuvant tamoxifen. Cancer 112: 1437-1444.
27. Lash TL, Fink AK (2003) Semi-automated sensitivity analysis to assess systematic errors in observational data. Epidemiology 14: 451-458.
28. Lash TL, Fox MP, Fink AK (2009) Applying Quantitative Bias Analysis to Epidemiologic Data. 1st edn, Springer
29. Lash TL, Fox MP, Thwin SS, Geiger AM, Buist DSM, Wei F, Field TS, Yood MU, Frost FJ, Quinn VP, Prout MN, Silliman RA (2007) Using probabilistic corrections to account for abstractor agreement in medical record reviews. Am J Epidemiol 165: 1454-1461.
30. Makubate B, Donnan PT, Dewar JA, Thompson AM, McCowan C (2013) Cohort study of adherence to adjuvant endocrine therapy, breast cancer recurrence and mortality. Br J Cancer 108(7): 1515-1524.
31. Maldonado G, Greenland S (1993) Simulation study of confounder-selection strategies. Am J Epidemiol 138: 923-936.
32. Mansell J, Monypenny IJ, Skene AI, Abram P, Carpenter R, Gattuso JM, Wilson CR, Angerson WJ, Doughty JC (2009) Patterns and predictors of early recurrence in postmenopausal women with estrogen receptorpositive early breast cancer. Breast Cancer Res Treat 117: 91-98.
33. McCowan C, Shearer J, Donnan PT, Dewar JA, Crilly M, Thompson AM, Fahey TP (2008) Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer. Br J Cancer 99: 1763-1768. NCRI (2012) Data Quality and Completeness at the Irish National Cancer Registry (Technical Report). National Cancer Registry Ireland.
34. Owusu C, Buist DSM, Field TS, Lash TL, Thwin SS, Geiger AM, Quinn VP, Frost F, Prout M, Yood MU, Wei F, Silliman RA (2008) Predictors of tamoxifen discontinuation among older women with estrogen receptorpositive breast cancer. J Clin Oncol 26: 549-555.
35. Partridge AH, Wang PS, Winer EP, Avorn J (2003) Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol 21: 602-606.
36. Pearce N (1993) What does the odds ratio estimate in a case-control study? Int J Epidemiol 22: 1189-1192.
37. Peterson AM, Nau DP, Cramer JA, Benner J, Gwadry-Sridhar F, Nichol M (2007) A checklist for medication compliance and persistence studies using retrospective databases. Value Health 10: 3-12.
38. Robins JM, Gail MH, Lubin JH (1986) More on 'Biased selection of controls for case-control analyses of cohort studies'. Biometrics 42: 293-299.
39. Rothman KJ, Greenland S, Lash TL (eds) (2008) Modern Epidemiology. 3rd edn, Lippincott Williams & Wilkins: Philadelphia, PA, pp 128-147.
40. Saphner T, Tormey DC, Gray R (1996) Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol 14: 2738-2746.
41. Schneeweiss S, Seeger JD, Maclure M, Wang PS, Avorn J, Glynn RJ (2001) Performance of comorbidity scores to control for confounding in epidemiologic studies using claims data. Am J Epidemiol 154: 854-864.
42. Suissa S (2007) Immortal time bias in observational studies of drug effects. Pharmacoepidemiol Drug Saf 16: 241-249.
43. Thwin SS, Clough-Gorr KM, McCarty MC, Lash TL, Alford SH, Buist DSM, Enger SM, Field TS, Frost F, Wei F, Silliman RA (2007) Automated interrater reliability assessment and electronic data collection in a multi-center breast cancer study. BMC Med Res Methodol 7: 23.
44. Weaver KE, Camacho F, Hwang W, Anderson R, Kimmick G (2012) Adherence to adjuvant hormonal therapy and its relationship to breast cancer recurrence and survival among low-income women. Am J Clin Oncol 36(2): 181-187.
45. WHO (2010) ATC classification index with DDDs 2011. WHO Collaborating Centre for Drug Statistics Methodology: Oslo.